[Hyperuricaemia and Chronic Kidney Disease]

Area of Science:

• Nephrology
• Cardiology
• Metabolic Disorders

Background:

• Hyperuricemia, defined as serum uric acid > 6 mg/dl, results from overproduction or reduced renal excretion.
• Prevalence in Italy is ~12%, rising to 60% in renal disease patients.
• Uric acid is implicated in arterial hypertension, arteriosclerosis, and increased cardiovascular risk.

Purpose of the Study:

• To review the role of hyperuricemia in cardiovascular and kidney disease.
• To compare febuxostat with allopurinol for hyperuricemia management.
• To discuss the potential of urate-lowering therapy in reducing cardiovascular events and slowing chronic kidney disease progression.

Main Methods:

• Review of experimental and observational studies.
• Analysis of randomized controlled trials (RCTs) comparing febuxostat and allopurinol.
• Discussion of ongoing RCTs focused on nephroprotective effects of urate-lowering treatments.

Main Results:

• Febuxostat demonstrated superior hyperuricemia control compared to allopurinol in RCTs.
• Observational studies suggest urate-lowering treatment may reduce cardiovascular events.
• Urate-lowering therapies may slow the progression of chronic kidney disease.

Conclusions:

• Hyperuricemia is an independent risk factor for de novo chronic kidney disease.
• Febuxostat offers effective hyperuricemia management.
• Further research, including ongoing RCTs, is needed to confirm the nephroprotective benefits of urate-lowering treatments.